An Online First version of this article was made available online at https ://rd.sprin ger.com/artic le/10.1007%2Fs40 261-018-0741-2 on 3 January 2019. An error was subsequently identified in the article, and the following correction should be noted:
The caption of Fig. 1 , which previously read:
" Fig. 1 Inhibition of ER/HER2 cross-talk with neratinib plus endocrine therapy. E oestrogen, ER oestrogen receptor, HR hormone receptor, HER2 human epidermal growth factor receptor 2" Should read:
" Fig. 1 Inhibition of ER/HER2 cross-talk with neratinib plus endocrine therapy. E oestrogen, ER oestrogen receptor, HR hormone receptor, HER2 human epidermal growth factor receptor 2. © Puma Biotechnology, 2018 (published with permission)"
The original article can be found online at https ://doi.org/10.1007/ s4026 1-018-0741-2.
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